跳至主要内容
临床试验/NCT03330002
NCT03330002已完成不适用

Post-Market Clinical Registry to Evaluate the Safety and Performance of MANTA Vascular Closure Device (VCD) Under Real World Conditions in the European Union (EU)

Essential Medical, Inc.9 个研究点 分布在 5 个国家目标入组 500 人开始时间: 2018年2月23日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
500
试验地点
9
主要终点
Number of Participants With One or More Major Access Site Related Complications

研究概览

简要总结

The aim of this observational post market study is to compile real world outcome data on the use of the Conformité Européenne (CE) marked MANTA Vascular Closure Device following percutaneous cardiac or peripheral procedures for large bore (10-18F ID) interventional devices.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

结局指标

主要结局

Number of Participants With One or More Major Access Site Related Complications

时间窗: within 30 days of procedure

Major access site related complications adapted from the VARC-2 definitions

Time to Hemostasis

时间窗: Immediately after deployment of MANTA VCD

The elapsed time between MANTA deployment (withdrawal of sheath from artery) and first observed and confirmed arterial hemostasis (no or minimal subcutaneous oozing and the absence of expanding or developing hematoma).

次要结局

  • Number of Participants With One or More Minor Access Site Related Complications(within 30 days of procedure)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (9)

Loading locations...

相似试验